نتایج جستجو برای: interleukin 28b
تعداد نتایج: 96973 فیلتر نتایج به سال:
BACKGROUND AND AIMS Genetic polymorphisms near interleukin 28B gene are associated with spontaneous and treatment induced clearance of hepatitis C virus (HCV). Our objective was to evaluate the impact of interleukin 28B single nucleotide polymorphism (rs12979860, rs8099917) variability in HCV genotype 3 infected populations. METHODS 400 hepatitis C seroreactive patients from different populat...
A rapid, duplex, high-resolution melting interleukin-28B gene (IL28B) genotyping assay, targeting both rs12979860 and rs8099917 polymorphisms, was developed and validated using 30 DNA samples from healthy volunteers. A linkage study on 300 healthy Singaporeans showed variable haplotypes. When the assay was applied to plasma DNA from 50 hepatitis C virus genotype-1 (HCV-1)-infected patients, fiv...
BACKGROUND The current stopping rule for peginterferon/ribavirin therapy in hepatitis C virus genotype-1 (HCV-1) patients is based on an early virological response (EVR, defined as >2 log(10) viral reduction at treatment week 12). We aimed to explore rapid stopping rules at week 4. METHODS We randomly allocated 528 HCV-1 patients into training and validation sets (at a 1∶2 ratio). The interle...
BACKGROUND Hepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylated interferon and ribavirin likely may remain a component of hepatitis C virus treatment for some patients. Unfortunately, pegylated interferon / ri...
Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000-1,...
In re: SUNTERRA CORPORATION SECURITIES LITIGATION. ) ) ) ) ) ) ) ) ) ) ) ) ) Case Nos. 6:00-cv-79-Orl-28B, 6:00-cv-97-Orl-28B, 6:00-cv-112Orl-28B, 6:00-cv115-Orl-28B, 6:00-cv-116-Orl28B, 6:00-cv-121-Orl-28B, 6:00cv-127-Orl-28B, 6:00-cv-128-Orl-28B, 6:00-cv-169Orl-28B, 6:00-cv-210-Orl-28B, 6:00-cv-268-Orl28B, 6:00-cv-278-Orl-28B, 6:00cv-285-Orl-28B, 6:00-cv-286-Orl28B, 6:00-cv321-Orl-28B
Interleukin 28B (IL28B) rs12979860 polymorphisms were examined in 41 individuals with human T-lymphotrophic virus type 1 (HTLV-1). The alleles CT/TT were more frequent in 12 individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis than in 29 asymptomatic carriers (80% vs 20%; P = .03), and median HTLV-1 proviral load was greater in CT/TT than CC carriers (P = .01). Thus, IL28B...
HCV infection is a serious public health problem and a leading cause of chronic liver disease. It affects nearly 3% of the world's population with an associated high mortality. Egypt has the highest prevalence of HCV infection in the world (estimated at >10%). Peg-IFN-α and RBV are the most widely used therapy for HCV. Unfortunately, the rate of SVR is around 50%. In addition, it is expensive a...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید